User:Tchristensen28/sandbox

This is my sandbox page. Edit this, not the talk page.

Plasminogen activators are serine proteases that catalyze the activation of plasmin via proteolytic cleavage of its zymogen form plasminogen. Plasmin is an important factor in fibrinolysis, the breakdown of fibrin polymers formed during blood clotting. There are two main plasminogen activators: urokinase and tissue plasminogen activator. Tissue plasminogen activators are used to treat medical conditions related to blood clotting including embolic or thrombotic stroke, myocardial infarction, and pulmonary embolism.

Function

Put some information here about the function of plasminogen activators, being sure to keep it clear that there are two different types.

Structure

I am not sure whether this section is called for, as uPA and tPA have different structures. However, if some information can be found citing a commonality in structure between the two, it should be covered here.

Urokinase

Maybe put information about the specific structure of urokinase here, without going into too much detail as there is an article dedicated to urokinase.

Tissue plasminogen activator

Do the same for tPA here.

Plasminogen activation system

I am not sure if there is enough material to give this its own heading, but possibly cover this here. The plasminogen activation system involves the interaction of plasminogen activators and their inhibitors, which all contribute to a balance of blood clotting and tissue reorganization.

Inhibition

Plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, and Protein C inhibitor are three factors that inhibit the action of plasminogen activators, and this should be discussed here.

Type 1 plasminogen activator inhibitor (PAI-1) is a serine protease inhibitor synthesized by endothelial cells and thought to play a crucial role in the regulation of fibrinolysis. PAI-1 is a glycoprotein, of which molecular weight is approximately 50,000. Molecular biological analyses indicate that PAI-1 is synthesized as a single polypeptide composed of 402 amino acids containing a signal peptide. PAI-1 is a physiological inhibitor of both tissue-type plasminogen activator and urokinase-type plasminogen activator, key enzymes in the initiation of fibrinolysis. Thus PAI-1 regulates not only blood clot lysis but also a wide variety of biological reactions occurring in extracellular matrices such as tumor metastasis, neovascularization, inflammation, and cell migration.

Applications

Tissue plasminogen activator is produced and sold as a medicine to treat blood clot related disorders and that should be covered here.

Urokinase also has medical applications and they can be covered here.

Cwelsh3- I think the lead section is good, I would recommend adding moles behind the molecular weight of PAI-1, or maybe expand on why the molecular weight is important.